128 related articles for article (PubMed ID: 3085684)
21. [Absorption, distribution, metabolism and excretion of netilmicin in rats (III). Metabolic fate of 14C-netilmicin after intramuscular administration (author's transl)].
Uda F; Fujino A; Tokiwa T
Jpn J Antibiot; 1982 Apr; 35(4):967-78. PubMed ID: 7097991
[TBL] [Abstract][Full Text] [Related]
22. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
Roth B; Cerny T; Brunner KW; Küpfer A
Schweiz Med Wochenschr; 1989 Aug; 119(34):1153-8. PubMed ID: 2510294
[TBL] [Abstract][Full Text] [Related]
23. Disposition and pharmacokinetics of phenethyl isothiocyanate and 6-phenylhexyl isothiocyanate in F344 rats.
Conaway CC; Jiao D; Kohri T; Liebes L; Chung FL
Drug Metab Dispos; 1999 Jan; 27(1):13-20. PubMed ID: 9884304
[TBL] [Abstract][Full Text] [Related]
24. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
Kunze E; Köhnecke B; Engelhardt W; Steinröder H; Brock N; Pohl J
Urol Int; 1984; 39(2):61-7. PubMed ID: 6426112
[TBL] [Abstract][Full Text] [Related]
25. Absorption, distribution and excretion of DL-gamma-amino-beta-hydroxybutyric acid-1-14C (GABOB-1-14C) in the rat.
Bonardi G; Mondino A; Silvestri S; Zanolo G
Arzneimittelforschung; 1981; 31(11):1910-3. PubMed ID: 7198473
[TBL] [Abstract][Full Text] [Related]
26. Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.
Al-Safi SA; Maddocks JL
Br J Clin Pharmacol; 1986 Mar; 21(3):267-70. PubMed ID: 2938613
[TBL] [Abstract][Full Text] [Related]
27. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
el-Yazigi A; Yusuf A; al-Rawithi S
Ther Drug Monit; 1995 Apr; 17(2):153-8. PubMed ID: 7624904
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of rat hepatic microsomal lipid peroxidation by mesna via glutathione.
Bast A; Haenen GR; Savenije-Chapel EM
Arzneimittelforschung; 1987 Sep; 37(9):1043-5. PubMed ID: 3124863
[TBL] [Abstract][Full Text] [Related]
29. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
[TBL] [Abstract][Full Text] [Related]
30. Fate of radioactive exocrine pancreatic proteins injected into the blood circulation of the rat. Tissue uptake and transepithelial excretion.
Rohr G; Scheele G
Gastroenterology; 1983 Nov; 85(5):991-1002. PubMed ID: 6618114
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 2nd communication: distribution to organs and tissues in male, female and pregnant rats, and characteristics of protein binding in plasma.
Steinke W; Ahr HJ; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):939-48. PubMed ID: 9296280
[TBL] [Abstract][Full Text] [Related]
32. Metabolism of 1-propyl-1-nitrosourea (PNU) in rats.
Tanaka A; Watanabe M
IARC Sci Publ; 1982; (41):483-91. PubMed ID: 7141555
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of [14C]acetylisoniazid and [14C]acetylhydrazine by the rat and rabbit.
Thomas BH; Whitehouse LW; Zeitz W
Fundam Appl Toxicol; 1984 Aug; 4(4):646-53. PubMed ID: 6479511
[TBL] [Abstract][Full Text] [Related]
34. Determination of sodium 2-mercaptoethanesulphonate by high-performance liquid chromatography using post-column reaction colorimetry or electrochemical detection.
Sidau B; Shaw IC
J Chromatogr; 1984 Nov; 311(1):234-8. PubMed ID: 6440899
[No Abstract] [Full Text] [Related]
35. Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys.
Holstege A; Pausch J; Gerok W
Cancer Res; 1986 Nov; 46(11):5576-81. PubMed ID: 3756903
[TBL] [Abstract][Full Text] [Related]
36. [Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
Schnitker J
Arzneimittelforschung; 1982; 32(10):1334-8. PubMed ID: 6817761
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of ciprofloxacin. 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C]ciprofloxacin in albino rats.
Siefert HM; Maruhn D; Scholl H
Arzneimittelforschung; 1986 Oct; 36(10):1503-10. PubMed ID: 3101707
[TBL] [Abstract][Full Text] [Related]
38. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
39. [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
Schmähl D; Habs M; Tacchi AM
Urologe A; 1984 Sep; 23(5):291-6. PubMed ID: 6438859
[TBL] [Abstract][Full Text] [Related]
40. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
Leeuwenkamp OR; Neijt JP; van der Vijgh WJ; Pinedo HM
Eur J Cancer; 1991; 27(10):1243-7. PubMed ID: 1835593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
